Mr. Todd Shapiro reports

RED LIGHT HOLLAND REPORTS CONTINUED EXPANSION OF FILAMENT HEALTH'S PEX010 CLINICAL NETWORK WITH NEW LICENSE AGREEMENTS AND RESEARCH SHIPMENTS

Red Light Holland Corp. target Filament Health Corp. has signed three new license agreements and completed two research shipments during March, 2026, further expanding the global clinical network for PEX010, Filament's patented botanical psilocybin drug candidate.

Red Light recently announced a definitive arrangement agreement to acquire Filament Health, including its portfolio of 76 issued patents across 15 patent families and its lead drug candidate, PEX010. On March 23, 2026, Filament obtained an interim order from the Supreme Court of British Columbia in connection with the proposed arrangement. The transaction remains subject to Filament shareholder approval, final court approval and other customary closing conditions.

New licence agreements

Recently, Filament entered into licence agreements with the following institutions for clinical research involving PEX010:

• University of Melbourne (Australia) -- for a study titled psilocybin-assisted physiotherapy for refractory functional neurological disorder;
• Imperial College London (United Kingdom) -- for a study titled PsiloGambling: Psilocybin in Gambling Disorder: multimodal brain and physiological biomarkers of action;
• University of Calgary (Canada) -- for a study titled psilocybin-assisted therapy for posttraumatic stress disorder in Survivors of Intimate Partner Violence.

Recent shipments

Filament also, recently, completed research shipments of PEX010 to the following institutions:

• Queen's University (Canada) -- for a pilot study titled safety and efficacy of psilocybin-assisted psychotherapy for demoralization syndrome in patients diagnosed with advanced-stage cancer;
• Centre for Addiction and Mental Health (CAMH) (Canada) -- a clinical trial titled treatment-resistant depression: a randomized phase II clinical trial comparing one versus two psychedelic doses of psilocybin.

"Each new agreement and shipment reinforces the growing global demand for standardized, naturally derived psilocybin in regulated clinical research," said Todd Shapiro, chief executive officer and director of Red Light Holland. "From helping patients with unexplained neurological symptoms in Australia to supporting survivors of intimate partner violence in Canada, the range of people PEX010 may be able to help continues to expand and we are proud to be supporting that progress."

"These agreements reflect the confidence that leading research institutions around the world place in PEX010 as a reliable, pharmaceutical-grade botanical psilocybin for clinical use," said Benjamin Lightburn, chief executive officer and director of Filament Health. "Our ability to deliver consistently to programs spanning oncology, PTSD, treatment-resistant depression and beyond speaks to the strength of our manufacturing platform and the breadth of unmet need in this space."

PEX010 has been supplied to over 70 clinical research sites worldwide and has been authorized for use in several federally authorized compassionate use programs. The drug candidate has received both Health Canada and United States Food and Drug Administration authorization for clinical trials in addition to authorization in 10 other jurisdictions globally.

About Red Light Holland Corp.

Red Light Holland is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and R&D (research-and-development) initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B (business-to-business) and DTC (direct-to-consumer) channels, in compliance with applicable laws.

About Filament Health Corp.

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.

We seek Safe Harbor.